ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance

Core Insights - Alphatec Holdings, Inc. reported preliminary revenue results for Q4 and full-year 2023, indicating strong growth in surgical and EOS revenues, with total revenue growth of approximately 37% for the year [1][2] - The company anticipates full-year 2024 total revenue of $595 million, reflecting a growth of approximately 23% to 24% compared to 2023 [3] Revenue Results - Q4 2023 surgical revenue is projected to be between $121.8 million and $122.8 million, while full-year surgical revenue is expected to be between $422.0 million and $423.0 million [1] - EOS revenue for Q4 2023 is estimated at $15.0 million to $15.6 million, with full-year EOS revenue expected to be between $59.1 million and $59.7 million [1] - Total revenue for Q4 2023 is projected to be between $136.8 million and $138.4 million, and for the full year, it is expected to be between $481.1 million and $482.7 million [1] Growth Drivers - The company experienced a surgical revenue growth of 39% to 40% for full-year 2023, driven by the strong performance of its lateral franchise, including PTP and LTP approaches [1] - Surgical volume growth accelerated to 31% in 2023, up from 25% in 2022, indicating robust demand for the company's offerings [1] Future Outlook - The company plans to report detailed financial results for Q4 and full-year 2023 on February 27, 2024, and will provide guidance for 2024 profitability [3] - An updated long-range financial plan will be shared on March 19, 2024, indicating the company's commitment to transparency and strategic planning [5] Company Vision - Alphatec aims to revolutionize spine surgery through its Organic Innovation Machine™, focusing on clinical distinction and the integration of its AlphaInformatiX Platform to enhance surgical outcomes [6] - The company emphasizes its commitment to becoming the Standard Bearer in Spine, leveraging its 100% focus on spine care to capture market share [2]